| Variables . | Overall . | Control group . | Intervention group . | P . |
|---|---|---|---|---|
| (n = 1829) . | (n = 860) . | (n = 969) . | ||
| Exit site | ||||
| Home, n (%) | 1697 (92.8) | 784 (91.2) | 913 (94.2) | .08 |
| Rehabilitation, n (%) | 71 (3.9) | 41 (4.8) | 30 (3.1) | |
| Death, n (%) | 9 (0.5) | 6 (0.7) | 3 (0.3) | |
| Other, n (%) | 52 (2.8) | 29 (3.4) | 23 (2.4) | |
| Antithrombotic therapy | ||||
| Aspirin, n (%) | 1194 (65.6) | 550 (64.4) | 644 (66.7) | .31 |
| Clopidogrel, n (%) | 585 (32.1) | 235 (27.5) | 350 (36.2) | <.0001 |
| DAPT, n (%) | 452 (24.8) | 193 (22.6) | 259 (26.8) | .04 |
| OAC, n (%) | 697 (38.3) | 326 (38.2) | 371 (38.4) | .92 |
| Causes of failed early discharge | ||||
| Conduction disturbances, n (%) | 450 (24.6) | 209 (24.3) | 241 (24.8) | <.0001 |
| Vascular complications, n (%) | 110 (6.0) | 59 (6.9) | 51 (5.3) | .76 |
| Bleeding complications, n (%) | 122 (6.7) | 70 (8.1) | 52 (5.4) | .57 |
| Neurological complications, n (%) | 61 (3.3) | 34 (4.0) | 27 (2.8) | .90 |
| Kidney complications, n (%) | 54 (3.0) | 28 (3.3) | 26 (2.7) | .63 |
| Infectious complications, n (%) | 58 (3.2) | 27 (3.1) | 31 (3.2) | .18 |
| Heart failure, n (%) | 37 (2.0) | 17 (2.0) | 20 (2.1) | .26 |
| Myocardial infarction, n (%) | 2 (0.1) | 1 (0.1) | 1 (0.1) | >.99 |
| Autonomy loss, n (%) | 33 (1.8) | 15 (1.7) | 18 (1.9) | .26 |
| Refusal, n (%) | 14 (0.8) | 9 (1.0) | 5 (0.5) | .49 |
| Logistic, n (%) | 26 (1.4) | 7 (0.8) | 19 (2.0) | .003 |
| Variables . | Overall . | Control group . | Intervention group . | P . |
|---|---|---|---|---|
| (n = 1829) . | (n = 860) . | (n = 969) . | ||
| Exit site | ||||
| Home, n (%) | 1697 (92.8) | 784 (91.2) | 913 (94.2) | .08 |
| Rehabilitation, n (%) | 71 (3.9) | 41 (4.8) | 30 (3.1) | |
| Death, n (%) | 9 (0.5) | 6 (0.7) | 3 (0.3) | |
| Other, n (%) | 52 (2.8) | 29 (3.4) | 23 (2.4) | |
| Antithrombotic therapy | ||||
| Aspirin, n (%) | 1194 (65.6) | 550 (64.4) | 644 (66.7) | .31 |
| Clopidogrel, n (%) | 585 (32.1) | 235 (27.5) | 350 (36.2) | <.0001 |
| DAPT, n (%) | 452 (24.8) | 193 (22.6) | 259 (26.8) | .04 |
| OAC, n (%) | 697 (38.3) | 326 (38.2) | 371 (38.4) | .92 |
| Causes of failed early discharge | ||||
| Conduction disturbances, n (%) | 450 (24.6) | 209 (24.3) | 241 (24.8) | <.0001 |
| Vascular complications, n (%) | 110 (6.0) | 59 (6.9) | 51 (5.3) | .76 |
| Bleeding complications, n (%) | 122 (6.7) | 70 (8.1) | 52 (5.4) | .57 |
| Neurological complications, n (%) | 61 (3.3) | 34 (4.0) | 27 (2.8) | .90 |
| Kidney complications, n (%) | 54 (3.0) | 28 (3.3) | 26 (2.7) | .63 |
| Infectious complications, n (%) | 58 (3.2) | 27 (3.1) | 31 (3.2) | .18 |
| Heart failure, n (%) | 37 (2.0) | 17 (2.0) | 20 (2.1) | .26 |
| Myocardial infarction, n (%) | 2 (0.1) | 1 (0.1) | 1 (0.1) | >.99 |
| Autonomy loss, n (%) | 33 (1.8) | 15 (1.7) | 18 (1.9) | .26 |
| Refusal, n (%) | 14 (0.8) | 9 (1.0) | 5 (0.5) | .49 |
| Logistic, n (%) | 26 (1.4) | 7 (0.8) | 19 (2.0) | .003 |
DAPT, dual antiplatelet therapy; OAC, oral anticoagulation.
| Variables . | Overall . | Control group . | Intervention group . | P . |
|---|---|---|---|---|
| (n = 1829) . | (n = 860) . | (n = 969) . | ||
| Exit site | ||||
| Home, n (%) | 1697 (92.8) | 784 (91.2) | 913 (94.2) | .08 |
| Rehabilitation, n (%) | 71 (3.9) | 41 (4.8) | 30 (3.1) | |
| Death, n (%) | 9 (0.5) | 6 (0.7) | 3 (0.3) | |
| Other, n (%) | 52 (2.8) | 29 (3.4) | 23 (2.4) | |
| Antithrombotic therapy | ||||
| Aspirin, n (%) | 1194 (65.6) | 550 (64.4) | 644 (66.7) | .31 |
| Clopidogrel, n (%) | 585 (32.1) | 235 (27.5) | 350 (36.2) | <.0001 |
| DAPT, n (%) | 452 (24.8) | 193 (22.6) | 259 (26.8) | .04 |
| OAC, n (%) | 697 (38.3) | 326 (38.2) | 371 (38.4) | .92 |
| Causes of failed early discharge | ||||
| Conduction disturbances, n (%) | 450 (24.6) | 209 (24.3) | 241 (24.8) | <.0001 |
| Vascular complications, n (%) | 110 (6.0) | 59 (6.9) | 51 (5.3) | .76 |
| Bleeding complications, n (%) | 122 (6.7) | 70 (8.1) | 52 (5.4) | .57 |
| Neurological complications, n (%) | 61 (3.3) | 34 (4.0) | 27 (2.8) | .90 |
| Kidney complications, n (%) | 54 (3.0) | 28 (3.3) | 26 (2.7) | .63 |
| Infectious complications, n (%) | 58 (3.2) | 27 (3.1) | 31 (3.2) | .18 |
| Heart failure, n (%) | 37 (2.0) | 17 (2.0) | 20 (2.1) | .26 |
| Myocardial infarction, n (%) | 2 (0.1) | 1 (0.1) | 1 (0.1) | >.99 |
| Autonomy loss, n (%) | 33 (1.8) | 15 (1.7) | 18 (1.9) | .26 |
| Refusal, n (%) | 14 (0.8) | 9 (1.0) | 5 (0.5) | .49 |
| Logistic, n (%) | 26 (1.4) | 7 (0.8) | 19 (2.0) | .003 |
| Variables . | Overall . | Control group . | Intervention group . | P . |
|---|---|---|---|---|
| (n = 1829) . | (n = 860) . | (n = 969) . | ||
| Exit site | ||||
| Home, n (%) | 1697 (92.8) | 784 (91.2) | 913 (94.2) | .08 |
| Rehabilitation, n (%) | 71 (3.9) | 41 (4.8) | 30 (3.1) | |
| Death, n (%) | 9 (0.5) | 6 (0.7) | 3 (0.3) | |
| Other, n (%) | 52 (2.8) | 29 (3.4) | 23 (2.4) | |
| Antithrombotic therapy | ||||
| Aspirin, n (%) | 1194 (65.6) | 550 (64.4) | 644 (66.7) | .31 |
| Clopidogrel, n (%) | 585 (32.1) | 235 (27.5) | 350 (36.2) | <.0001 |
| DAPT, n (%) | 452 (24.8) | 193 (22.6) | 259 (26.8) | .04 |
| OAC, n (%) | 697 (38.3) | 326 (38.2) | 371 (38.4) | .92 |
| Causes of failed early discharge | ||||
| Conduction disturbances, n (%) | 450 (24.6) | 209 (24.3) | 241 (24.8) | <.0001 |
| Vascular complications, n (%) | 110 (6.0) | 59 (6.9) | 51 (5.3) | .76 |
| Bleeding complications, n (%) | 122 (6.7) | 70 (8.1) | 52 (5.4) | .57 |
| Neurological complications, n (%) | 61 (3.3) | 34 (4.0) | 27 (2.8) | .90 |
| Kidney complications, n (%) | 54 (3.0) | 28 (3.3) | 26 (2.7) | .63 |
| Infectious complications, n (%) | 58 (3.2) | 27 (3.1) | 31 (3.2) | .18 |
| Heart failure, n (%) | 37 (2.0) | 17 (2.0) | 20 (2.1) | .26 |
| Myocardial infarction, n (%) | 2 (0.1) | 1 (0.1) | 1 (0.1) | >.99 |
| Autonomy loss, n (%) | 33 (1.8) | 15 (1.7) | 18 (1.9) | .26 |
| Refusal, n (%) | 14 (0.8) | 9 (1.0) | 5 (0.5) | .49 |
| Logistic, n (%) | 26 (1.4) | 7 (0.8) | 19 (2.0) | .003 |
DAPT, dual antiplatelet therapy; OAC, oral anticoagulation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
